Cardiff Oncology (CRDF) has completed enrollment for the phase 2 trial assessing a combination of its onvansertib drug candidate with the standard of care in patients with first-line, RAS-mutated metastatic colorectal cancer.

Patients across 41 clinical sites in the US are randomized into either 20- or 30-milligram onvansertib plus standard of care, or standard of care alone. The study has a primary endpoint of an objective response rate and secondary endpoints including progression-free survival, duration of response and safety, the company said.

Cardiff said it expects to report additional clinical data from the mid-stage trial later during the current quarter.

Cardiff shares recently were fractionally higher during Tuesday's after-hours session.